P. DiSilvestro

发表

Inherited Mutations in Women With Ovarian Carcinoma.

Tom Walsh, Nilsa C Ramirez, Robert S Mannel, 2016, JAMA oncology.

SOLO1 and SOLO2: Randomized phase III trials of olaparib in patients (pts) with ovarian cancer and a BRCA1/2 mutation (BRCAm).

P. DiSilvestro, K. Moore, E. Lowe, 2014 .

Evaluation of the Diagnostic Accuracy of the Risk of Ovarian Malignancy Algorithm in Women With a Pelvic Mass

Richard G. Moore, S. Skates, J. Ball, 2011, Obstetrics and gynecology.

A randomized phase III trial of cisplatin and tumor volume directed irradiation followed by carboplatin and paclitaxel vs. carboplatin and paclitaxel for optimally debulked, advanced endometrial carcinoma.

D. Matei, D. Mutch, D. Miller, 2017 .

Validation of a Multivariate Serum Profile for Epithelial Ovarian Cancer Using a Prospective Multi-Site Collection

B. Karlan, Jinghua Zhao, R. Alvarez, 2010 .

Bevacizumab and paclitaxel-carboplatin chemotherapy and secondary cytoreduction in recurrent, platinum-sensitive ovarian cancer (NRG Oncology/Gynecologic Oncology Group study GOG-0213): a multicentre, open-label, randomised, phase 3 trial.

R. Ashfaq, P. Sabbatini, J. Chan, 2017, The Lancet. Oncology.

A phase II evaluation of belinostat and carboplatin in the treatment of recurrent or persistent platinum-resistant ovarian, fallopian tube, or primary peritoneal carcinoma: a Gynecologic Oncology Group study.

Joan L. Walker, D. Dizon, P. DiSilvestro, 2012, Gynecologic oncology.

Niraparib monotherapy for late-line treatment of ovarian cancer (QUADRA): a multicentre, open-label, single-arm, phase 2 trial.

B. Monk, D. Matei, A. Oza, 2019, The Lancet. Oncology.

Patient reported outcomes for cisplatin and radiation followed by carboplatin/paclitaxel versus carboplatin/paclitaxel for locally advanced endometrial carcinoma: An NRG oncology study.

W. E. Richards, D. Matei, D. Mutch, 2021, Gynecologic oncology.

Adjuvant Chemotherapy plus Radiation for Locally Advanced Endometrial Cancer.

W. E. Richards, D. Matei, W. Small, 2019, The New England journal of medicine.

Treatment of Cervical Intraepithelial Neoplasia Levels 2 and 3 with Adapalene, a Retinoid‐Related Molecule

M. Pfahl, R. Mannel, P. DiSilvestro, 2001, Journal of lower genital tract disease.

Human Epididymis Protein 4 Promotes Events Associated with Metastatic Ovarian Cancer via Regulation of the Extracelluar Matrix

Richard G. Moore, N. Yano, P. DiSilvestro, 2018, Front. Oncol..

Pathologic findings at risk-reducing salpingo-oophorectomy: primary results from Gynecologic Oncology Group Trial GOG-0199.

D. Alberts, L. Minasian, M. Greene, 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

HE4 suppresses the expression of osteopontin in mononuclear cells and compromises their cytotoxicity against ovarian cancer cells

N. Yano, P. DiSilvestro, R. Singh, 2018, Clinical and experimental immunology.

Diagnosis and Management of Embryonal Rhabdomyosarcoma in a Woman with Prolapsing Cervical Mass

P. DiSilvestro, E. Connor, 2015 .

Septin-2 is overexpressed in epithelial ovarian cancer and mediates proliferation via regulation of cellular metabolic proteins

Richard G. Moore, N. Ahsan, N. Yano, 2019, Oncotarget.

Superior venacava syndrome

P. DiSilvestro, M. Pearl, F. Valea, 2002 .

Lower uterine segment involvement as a predictor for lymph node spread in endometrial carcinoma.

Richard G. Moore, P. DiSilvestro, C. Granai, 2007, Gynecologic oncology.

The prognostic significance of lower uterine segment involvement in surgically staged endometrial cancer patients with negative nodes

Richard G. Moore, P. DiSilvestro, C. Granai, 2007 .

BEVACZIUMAB PLUS FOSBRETABULIN IN RECURRENT OVARIAN CANCER: OVERALL SURVIVAL AND EXPLORATORY ANALYSES OF A RANDOMIZED PHASE II NRG ONCOLOGY/GYNECOLOGIC ONCOLOGY GROUP STUDY

B. Monk, R. Coleman, C. Aghajanian, 2021 .

Phase II trial of ixabepilone as second-line treatment in advanced endometrial cancer: gynecologic oncology group trial 129-P.

R. Alvarez, D. Dizon, P. DiSilvestro, 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

CT perfusion as an early biomarker of treatment efficacy in advanced ovarian cancer: An ECOG-ACRIN and NRG GOG study.

Ting-Yim Lee, C. Ng, J. Chan, 2015 .

Anal Cytology and Human Papillomavirus Genotyping in Women With a History of Lower Genital Tract Neoplasia Compared With Low-Risk Women

C. Raker, K. Robison, M. Clark, 2015, Obstetrics and gynecology.

Comparison of tolerance of combination carboplatin and paclitaxel chemotherapy by age in women with ovarian cancer.

P. DiSilvestro, M. Pearl, F. Valea, 2002, Gynecologic oncology.

Willingness of gynecologic cancer patients to participate in clinical trials.

C. Raker, S. Weitzen, P. DiSilvestro, 2009, Gynecologic oncology.

Cytoreductive surgery for ovarian cancer: quality assessment.

J. Berek, P. DiSilvestro, A. Brand, 2017, Annals of oncology : official journal of the European Society for Medical Oncology.

Pilot Phase 2 Trial of 4 Months of Maintenance Pegylated Liposomal Doxorubicin in Patients with Advanced Ovarian Cancer after Complete Response to Platinum and Paclitaxel-Based Chemotherapy

P. DiSilvestro, M. Pearl, F. Valea, 2006, Gynecologic and Obstetric Investigation.

Maintenance Treatment of Newly Diagnosed Advanced Ovarian Cancer: Time for a Paradigm Shift?

I. Ray-Coquard, R. Coleman, N. Colombo, 2021, Cancers.

Addressing clinical trials: can the multidisciplinary Tumor Board improve participation? A study from an academic women's cancer program.

C. Raker, A. Stuckey, D. Dizon, 2010, Gynecologic oncology.

While women await surgery for type I endometrial cancer, depot medroxyprogesterone acetate reduces tumor glandular cellularity

K. Robison, P. DiSilvestro, V. Danilack, 2018, American journal of obstetrics and gynecology.

The Perfect Combination: Enhancing Patient Response to PD-1-Based Therapies in Epithelial Ovarian Cancer

P. DiSilvestro, Jennifer R. Ribeiro, J. Ribeiro, 2020, Cancers.

Combined Microsatellite Instability, MLH1 Methylation Analysis, and Immunohistochemistry for Lynch Syndrome Screening in Endometrial Cancers From GOG210: An NRG Oncology and Gynecologic Oncology Group Study

F. Gao, P. Goodfellow, L. Brinton, 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Consensus in controversy: The modified Delphi method applied to Gynecologic Oncology practice.

B. Karlan, D. Mukamel, L. Havrilesky, 2015, Gynecologic oncology.

Maintenance treatment of recurrent ovarian cancer: Is it ready for prime time?

P. DiSilvestro, A. Alvarez Secord, 2018, Cancer treatment reviews.

For Women Receiving Chemotherapy for Clinically Apparent Early Ovarian Cancer, Is There a Benefit to Surgical Staging?

S. Weitzen, D. Dizon, P. DiSilvestro, 2008, American journal of clinical oncology.

A phase I/II study of chemo-immunotherapy with durvalumab (durva) and pegylated liposomal doxorubicin (PLD) in platinum-resistant recurrent ovarian cancer (PROC).

G. Coukos, P. Sabbatini, P. Schwarzenberger, 2018, Annals of Oncology.

Radiotherapy Versus Inguinofemoral Lymphadenectomy as Treatment for Vulvar Cancer Patients With Micrometastases in the Sentinel Node: Results of GROINSS-V II

H. Putter, B. Monk, D. Provencher, 2021, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Maintenance olaparib for patients with newly diagnosed advanced ovarian cancer and a BRCA mutation (SOLO1/GOG 3004): 5-year follow-up of a randomised, double-blind, placebo-controlled, phase 3 trial.

A. Oza, M. Friedlander, Byoung-Gie Kim, 2021, The Lancet. Oncology.

Late-Breaking Abstract 1: Randomized phase III noninferiority trial of first line chemotherapy for metastatic or recurrent endometrial carcinoma: A Gynecologic Oncology Group study

D. Miller, Takashi Matsumoto, G. Fleming, 2012 .

Panniculectomy in morbidly obese gynecologic oncology patients.

P. DiSilvestro, M. Pearl, F. Valea, 2000, International journal of surgical investigation.

Variations in patient preferences over side effects of treatments for ovarian cancer: Baseline results of a randomized controlled clinical trial

D. Mukamel, L. Havrilesky, R. Alvarez, 2017 .

Malignant Mixed Mesodermal Tumors of the Ovary

P. DiSilvestro, W. Gajewski, H. Kourea, 1995, Obstetrics and gynecology.

Randomized Phase III Trial of Paclitaxel and Carboplatin Versus Paclitaxel and Ifosfamide in Patients With Carcinosarcoma of the Uterus or Ovary: An NRG Oncology Trial

D. Mutch, A. Secord, D. Miller, 2022, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Long-term follow-up of vulvar cancer patients evaluated with sentinel lymph node biopsy alone.

Dario R. Roque, Richard G. Moore, K. Robison, 2014, Gynecologic oncology.

Urinary symptoms and impact on quality of life in women after treatment for endometrial cancer

V. Sung, D. Myers, P. DiSilvestro, 2009, International Urogynecology Journal.

1A randomized phase III trial of pelvic radiation therapy (PXRT) versus vaginal cuff brachytherapy followed by paclitaxel/carboplatin chemotherapy (VCB/C) in patients with high risk (HR), early stage endometrial cancer (EC): A Gynecologic Oncology Group trial

J. W. Kim, T. Rutherford, C. Aghajanian, 2014 .

QUADRA: A phase 2, open-label, single-arm study to evaluate niraparib in patients (pts) with relapsed ovarian cancer (ROC) who have received ≥3 prior chemotherapy regimens.

B. Monk, A. Oza, J. Berek, 2018 .

Oral thalidomide as palliative chemotherapy in women with advanced ovarian cancer.

Richard G. Moore, S. Weitzen, D. Dizon, 2007, Journal of Palliative Medicine.

Primary care experience on a university-based gynecologic oncology service

P. DiSilvestro, M. Pearl, F. Valea, 2002 .

Lifestyle intervention in ovarian cancer enhanced survival (LIVES) study (NRG/GOG0225): Recruitment, retention and baseline characteristics of a randomized trial of diet and physical activity in ovarian cancer survivors.

D. Alberts, E. Ratner, L. Kachnic, 2023, Gynecologic oncology.

A phase II evaluation of pazopanib in the treatment of recurrent or persistent carcinosarcoma of the uterus: a gynecologic oncology group study.

P. Thaker, K. Moxley, R. Zuna, 2014, Gynecologic oncology.

Maintenance Olaparib in Patients with Newly Diagnosed Advanced Ovarian Cancer

Gabe S. Sonke, Anne Floquet, Kathleen Moore, 2018, The New England journal of medicine.

InheritedMutations inWomenWith Ovarian Carcinoma

M. King, R. Burger, Ming K. Lee, 2016 .

An NRG Oncology/GOG study of molecular classification for risk prediction in endometrioid endometrial cancer.

D. Tritchler, P. Goodfellow, D. Mutch, 2018, Gynecologic oncology.

A phase I trial of pegylated liposomal doxorubicin (PLD), carboplatin, bevacizumab and veliparib in recurrent, platinum-sensitive ovarian, primary peritoneal, and fallopian tube cancer: An NRG Oncology/Gynecologic Oncology Group study.

P. Fracasso, L. Landrum, P. DiSilvestro, 2015, Gynecologic oncology.

FGFR2 mutations are associated with poor outcomes in endometrioid endometrial cancer: An NRG Oncology/Gynecologic Oncology Group study.

P. Pollock, S. Byron, P. Goodfellow, 2017, Gynecologic oncology.

Phase II trial of trastuzumab in women with advanced or recurrent, HER2-positive endometrial carcinoma: a Gynecologic Oncology Group study.

J. Berek, J. Fiorica, G. Fleming, 2010, Gynecologic oncology.

234O Maintenance olaparib for patients (pts) with newly diagnosed, advanced ovarian cancer (OC) and a BRCA mutation (BRCAm): 5-year (y) follow-up (f/u) from SOLO1

M. Friedlander, C. Aghajanian, A. Leary, 2020, Annals of Oncology.

Veliparib with First-Line Chemotherapy and as Maintenance Therapy in Ovarian Cancer.

M. Morgan, A. Okamoto, D. Cella, 2019, The New England journal of medicine.

Risk-Reducing Salpingo-Oophorectomy and Breast Cancer Risk Reduction in the Gynecologic Oncology Group Protocol-0199 (GOG-0199).

M. Gail, M. Greene, M. Sherman, 2019, JNCI cancer spectrum.

Clinicopathologic Significance of Mismatch Repair Defects in Endometrial Cancer: An NRG Oncology/Gynecologic Oncology Group Study.

D. Tritchler, P. Goodfellow, N. Ramirez, 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Inhibition of DUSP6 sensitizes ovarian cancer cells to chemotherapeutic agents via regulation of ERK signaling response genes

J. Emerson, N. Yano, C. Chichester, 2019, Oncotarget.

Two for good measure: six versus eight cycles of carboplatin and paclitaxel as adjuvant treatment for epithelial ovarian cancer.

Richard O. Moore, S. Weitzen, A. Rojan, 2006, Gynecologic oncology.

Weekly vs. Every-3-Week Paclitaxel and Carboplatin for Ovarian Cancer.

B. Monk, M. Birrer, S. Rubin, 2016, The New England journal of medicine.

Ki-67 Expression in a Cervical Cancer Organotypic Model Correlates with Growth and EGF-R Expression.

S. Lightfoot, P. DiSilvestro, D. Benbrook, 1999, Journal of lower genital tract disease.

Carboplatin and Paclitaxel for Advanced Endometrial Cancer: Final Overall Survival and Adverse Event Analysis of a Phase III Trial (NRG Oncology/GOG0209).

D. Cella, D. Miller, Takashi Matsumoto, 2020, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

A phase II evaluation of AMG 102 (rilotumumab) in the treatment of persistent or recurrent epithelial ovarian, fallopian tube or primary peritoneal carcinoma: a Gynecologic Oncology Group study.

M. Shahin, M. Goodheart, L. Landrum, 2014, Gynecologic oncology.

Secondary Surgical Cytoreduction for Recurrent Ovarian Cancer.

Danielle M. Enserro, Jae-Weon Kim, P. Sabbatini, 2019, The New England journal of medicine.

A novel multiple marker bioassay utilizing HE4 and CA125 for the prediction of ovarian cancer in patients with a pelvic mass.

Steven J Skates, Richard G. Moore, R. Bast, 2009, Gynecologic oncology.

The biomarker HE4 (WFDC2) promotes a pro-angiogenic and immunosuppressive tumor microenvironment via regulation of STAT3 target genes

Richard G. Moore, J. Emerson, Rakesh K. Singh, 2020, Scientific Reports.

The use of multiple novel tumor biomarkers for the detection of ovarian carcinoma in patients with a pelvic mass.

Thorsten Verch, Richard G. Moore, R. Bast, 2008, Gynecologic oncology.

GOG 8020/210: Risk stratification of lymph node metastasis, disease progression and survival using single nucleotide polymorphisms in endometrial cancer: An NRG oncology/gynecologic oncology group study.

P. Goodfellow, M. Birrer, D. Mutch, 2019, Gynecologic oncology.

Overall Survival With Maintenance Olaparib at a 7-Year Follow-Up in Patients With Newly Diagnosed Advanced Ovarian Cancer and a BRCA Mutation: The SOLO1/GOG 3004 Trial

A. Oza, Byoung-Gie Kim, M. Friedlander, 2022, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Patient-centred outcomes and effect of disease progression on health status in patients with newly diagnosed advanced ovarian cancer and a BRCA mutation receiving maintenance olaparib or placebo (SOLO1): a randomised, phase 3 trial.

A. Oza, E. Parkhomenko, M. Friedlander, 2021, The Lancet. Oncology.

Efficacy of Maintenance Olaparib for Patients With Newly Diagnosed Advanced Ovarian Cancer With a BRCA Mutation: Subgroup Analysis Findings From the SOLO1 Trial.

A. Oza, M. Friedlander, Byoung-Gie Kim, 2020, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Human Epididymis Secretory Protein 4 (HE4) Compromises Cytotoxic Mononuclear Cells via Inducing Dual Specificity Phosphatase 6

Richard G. Moore, N. Yano, C. Chichester, 2019, Front. Pharmacol..

Cross-sensitivity between paclitaxel and docetaxel in a women's cancers program.

Richard O. Moore, A. Rojan, D. Dizon, 2006, Gynecologic oncology.

A Randomized Controlled Trial of a Regular Diet as the First Meal in Gynecologic Oncology Patients Undergoing Intraabdominal Surgery

P. DiSilvestro, M. Pearl, F. Valea, 2002, Obstetrics and gynecology.

A Nonsynonymous Polymorphism in IRS1 Modifies Risk of Developing Breast and Ovarian Cancers in BRCA1 and Ovarian Cancer in BRCA2 Mutation Carriers

W. Chung, V. Pankratz, F. Couch, 2012, Cancer Epidemiology, Biomarkers & Prevention.

Circulating Tumor Cells In Advanced Cervical Cancer: NRG Oncology—Gynecologic Oncology Group Study 240 (NCT 00803062)

B. Monk, M. Birrer, L. Ramondetta, 2020, Molecular Cancer Therapeutics.

Bevacizumab plus fosbretabulin in recurrent ovarian cancer: Overall survival and exploratory analyses of a randomized phase II NRG oncology/gynecologic oncology group study.

B. Monk, S. Rubin, R. Coleman, 2020, Gynecologic oncology.

Randomized Trial of Intravenous Versus Intraperitoneal Chemotherapy Plus Bevacizumab in Advanced Ovarian Carcinoma: An NRG Oncology/Gynecologic Oncology Group Study.

D. Alberts, S. Rubin, H. Gray, 2019, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

An original phylogenetic approach identified mitochondrial haplogroup T1a1 as inversely associated with breast cancer risk in BRCA2 mutation carriers

W. Chung, R. Nussbaum, D. Steinemann, 2015, Breast Cancer Research.

phylogenetic approach identified mitochondrial haplogroup T 1 a 1 as inversely associated with breast cancer risk in BRCA 2 mutation carriers

W. Chung, D. Steinemann, V. Pankratz, 2015 .

Population-adjusted indirect treatment comparison of the SOLO1 and PAOLA-1/ENGOT-ov25 trials evaluating maintenance olaparib or bevacizumab or the combination of both in newly diagnosed, advanced BRCA-mutated ovarian cancer.

K. Rhodes, I. Vergote, I. Ray-Coquard, 2021, European journal of cancer.

Phase III Trial: Adjuvant Pelvic Radiation Therapy Versus Vaginal Brachytherapy Plus Paclitaxel/Carboplatin in High-Intermediate and High-Risk Early Stage Endometrial Cancer.

Jae-Weon Kim, W. Small, D. Miller, 2019, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Adjuvant Therapy in Node-Positive Endometrial Cancer: A Focus on Chemotherapy

P. DiSilvestro, Erin Lips, Julia Dexter, 2022, Current Oncology Reports.

A Phase 3 Trial of Pelvic Radiation Therapy Versus Vaginal Cuff Brachytherapy Followed by Paclitaxel/Carboplatin Chemotherapy in Patients with High-Risk, Early-Stage Endometrial Cancer: A Gynecology Oncology Group Study

W. Small, D. Miller, C. Yashar, 2017 .

Maintenance olaparib for patients with newly diagnosed, advanced ovarian cancer and a BRCA mutation: 5-year follow-up from SOLO1

A. Oza, M. Friedlander, Byoung-Gie Kim, 2021, Gynecologic Oncology.

Utility of PET-CT to evaluate retroperitoneal lymph node metastasis in advanced cervical cancer: Results of ACRIN6671/GOG0233 trial.

J. W. Kim, Shamshad Ali, L. Landrum, 2016, Gynecologic oncology.

Phase III randomized trial of weekly cisplatin and irradiation versus cisplatin and tirapazamine and irradiation in stages IB2, IIA, IIB, IIIB, and IVA cervical carcinoma limited to the pelvis: a Gynecologic Oncology Group study.

B. Monk, C. Muller, Shamshad Ali, 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Nomograms Predicting Progression-Free Survival, Overall Survival, and Pelvic Recurrence in Locally Advanced Cervical Cancer Developed From an Analysis of Identifiable Prognostic Factors in Patients From NRG Oncology/Gynecologic Oncology Group Randomized Trials of Chemoradiotherapy.

James Java, P. DiSilvestro, J. Java, 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Phase II study of carboplatin, paclitaxel, and bevacizumab with maintenance bevacizumab as first-line chemotherapy for advanced mullerian tumors.

S. Cannistra, U. Matulonis, N. Horowitz, 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

CT Perfusion as an Early Biomarker of Treatment Efficacy in Advanced Ovarian Cancer: An ACRIN and GOG Study

Ting-Yim Lee, C. Ng, J. Chan, 2017, Clinical Cancer Research.

Anal and Cervical High-Risk Human Papillomavirus Genotyping in Women With and Without Genital Neoplasia

C. Raker, K. Robison, M. Clark, 2018, Journal of lower genital tract disease.

A phase I study with an expanded cohort to assess feasibility of intravenous docetaxel, intraperitoneal carboplatin and intraperitoneal paclitaxel in patients with previously untreated ovarian, fallopian tube or primary peritoneal carcinoma: a Gynecologic Oncology Group study.

P. Fracasso, P. Thaker, S. Waggoner, 2012, Gynecologic oncology.

A phase I study with an expanded cohort to assess the feasibility of intravenous paclitaxel, intraperitoneal carboplatin and intraperitoneal paclitaxel in patients with untreated ovarian, fallopian tube or primary peritoneal carcinoma: a Gynecologic Oncology Group study.

P. Fracasso, P. Thaker, S. Waggoner, 2012, Gynecologic oncology.

Isolated sentinel lymph node dissection with conservative management in patients with squamous cell carcinoma of the vulva: a prospective trial.

Richard G. Moore, K. Robison, P. DiSilvestro, 2008, Gynecologic oncology.

A randomized phase II/III study of paclitaxel/carboplatin/metformin versus paclitaxel/carboplatin/placebo as initial therapy for measurable stage III or IVA, stage IVB, or recurrent endometrial cancer: An NRG Oncology/GOG study

S. Waggoner, A. Hagemann, C. Aghajanian, 2020 .

Unilateral inguinofemoral lymphadenectomy in patients with early-stage vulvar squamous cell carcinoma and a unilateral metastatic sentinel lymph node is safe.

B. Monk, D. Cruickshank, M. Widschwendter, 2022, Gynecologic oncology.

Radiotherapy instead of inguinofemoral lymphadenectomy in vulvar cancer patients with a metastatic sentinel node: results of GROINSS-V II

D. Provencher, D. Cruickshank, M. Widschwendter, 2019, International Journal of Gynecological Cancer.

A phase I/II study of extended field radiation therapy with concomitant paclitaxel and cisplatin chemotherapy in patients with cervical carcinoma metastatic to the para-aortic lymph nodes: a Gynecologic Oncology Group study.

Joan L. Walker, P. DiSilvestro, V. V. von Gruenigen, 2009, Gynecologic oncology.

Utility of PET/CT to Evaluate Retroperitoneal Lymph Node Metastasis in High-Risk Endometrial Cancer: Results of ACRIN 6671/GOG 0233 Trial.

S. King, Shamshad Ali, R. Mannel, 2017, Radiology.

P. DiSilvestro, C. Mathews, Kamaljeet Singh, 2021, Gynecologic oncology reports.

A randomized, double-blind phase III trial of niraparib maintenance treatment in patients with HRD+ advanced ovarian cancer after response to front-line platinum-based chemotherapy.

B. Monk, I. Vergote, R. Coleman, 2016 .

Evaluation of anal cytology and dysplasia in women with a history of lower genital tract dysplasia and malignancy.

C. Raker, K. Robison, C. Sung, 2016, Gynecologic oncology.

Tolerability of maintenance olaparib in newly diagnosed patients with advanced ovarian cancer and a BRCA mutation in the randomized phase III SOLO1 trial

Jae-Weon Kim, A. Oza, M. Friedlander, 2021, Gynecologic oncology.

Baseline platelet count and body weight as predictors of early dose modification in the quadra trial of niraparib monotherapy for the treatment of heavily pretreated (≥4th line), advanced, recurrent high-grade serous ovarian cancer

B. Monk, A. Oza, J. Berek, 2019, Gynecologic Oncology.

Radiation therapy with concomitant paclitaxel and cisplatin chemotherapy in cervical carcinoma limited to the pelvis: a phase I/II study of the Gynecologic Oncology Group.

Joan L. Walker, P. DiSilvestro, P. Rose, 2006, Gynecologic oncology.

811MO Maintenance olaparib for patients (pts) with newly diagnosed, advanced ovarian cancer (OC) and a BRCA mutation (BRCAm): 5-year (y) follow-up (f/u) from SOLO1

A. Oza, M. Friedlander, C. Aghajanian, 2020 .

392 Maintenance olaparib in patients with newly diagnosed advanced ovarian cancer and a BRCA mutation: subgroup analysis by risk in the phase III solo1 study

M. Friedlander, N. Colombo, G. Scambia, 2020 .

Is age a prognostic biomarker for survival among women with locally advanced cervical cancer treated with chemoradiation? An NRG Oncology/Gynecologic Oncology Group ancillary data analysis.

J. Thigpen, P. DiSilvestro, J. Java, 2016, Gynecologic oncology.

The prognostic significance of lower uterine segment involvement in surgically staged endometrial cancer patients with negative nodes.

Richard G. Moore, P. DiSilvestro, C. Granai, 2007, Gynecologic oncology.

Surgical-pathological findings in type 1 and 2 endometrial cancer: An NRG Oncology/Gynecologic Oncology Group study on GOG-210 protocol.

D. Mutch, S. Waggoner, J. Boggess, 2017, Gynecologic Oncology.

A phase I pharmacokinetic study of intraperitoneal bortezomib and carboplatin in patients with persistent or recurrent ovarian cancer: An NRG Oncology/Gynecologic Oncology Group study.

P. Fracasso, S. Howell, A. Hagemann, 2017, Gynecologic oncology.

Prognostic value of clinical variables in ovarian cancer.

P. DiSilvestro, C. Granai, J. Hogan, 1997, Journal of clinical epidemiology.

Outcomes of Endometrial Cancer Patients Undergoing Surgery With Gynecologic Oncology Involvement

P. DiSilvestro, M. Pearl, F. Valea, 2002, Obstetrics and gynecology.

17 Safety and patient-reported outcomes in patients receiving niraparib in the PRIMA/ENGOT-OV26/GOG-3012 trial

K. Jardon, P. Follana, F. Heitz, 2020 .

Analysis of tumour samples from SOLO1: Frequency of BRCA specific loss of heterozygosity (LOH) and progression-free survival (PFS) according to homologous recombination repair deficiency (HRD)-LOH score

J. Barrett, D. Hodgson, T. French, 2019, Annals of Oncology.

Maintenance olaparib following platinum-based chemotherapy in newly diagnosed patients (pts) with advanced ovarian cancer (OC) and a BRCA1/2 mutation (BRCAm): Phase III SOLO1 trial.

A. Oza, M. Friedlander, C. Aghajanian, 2018, Annals of oncology : official journal of the European Society for Medical Oncology.

Maintenance olaparib after platinum-based chemotherapy in patients (pts) with newly diagnosed advanced ovarian cancer (OC) and a BRCA mutation (BRCAm): Efficacy by surgical and tumor status in the Phase III SOLO1 trial.

A. Oza, M. Friedlander, Byoung-Gie Kim, 2019, Journal of Clinical Oncology.

Management of Low-Grade Cervical Müllerian Adenosarcoma in a 14-Year-Old Girl.

P. DiSilvestro, C. Mathews, E. Kalife, 2017, Journal of pediatric and adolescent gynecology.

Safety of maintenance bevacizumab after first-line chemotherapy for advanced ovarian and mullerian cancers

S. Cannistra, U. Matulonis, N. Horowitz, 2007 .

Malignancies arising in endometriosis

P. DiSilvestro, N. Gould, M. Gold, 1999 .

Abstract NT-101: QUADRA: A PHASE 2, OPEN-LABEL, SINGLE-ARM STUDY TO EVALUATE SINGLE-AGENT NIRAPARIB TREATMENT IN PATIENTS WITH RELAPSED OVARIAN CANCER (ROC) WHO HAVE RECEIVED ≥3 PRIOR CHEMOTHERAPY REGIMENS

B. Monk, A. Oza, J. Berek, 2019 .

Randomized Trial of Intravenous Versus Intraperitoneal Chemotherapy Plus Bevacizumab in Advanced Ovarian Carcinoma: An NRG Oncology/Gynecologic Oncology Group Study.

D. Alberts, S. Rubin, H. Gray, 2019, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Inherited Mutations in Women With Ovarian Carcinoma.

T. Walsh, M. King, R. Burger, 2016, JAMA oncology.

R. Ashfaq, P. Sabbatini, J. Chan, 2017, The Lancet. Oncology.

A novel multiple marker bioassay utilizing HE4 and CA125 for the prediction of ovarian cancer in patients with a pelvic mass.

Richard G. Moore, R. Bast, J. Dungan, 2009, Gynecologic oncology.

Weekly vs. Every-3-Week Paclitaxel and Carboplatin for Ovarian Cancer.

B. Monk, M. Birrer, S. Rubin, 2016, The New England journal of medicine.

Shaping the standard of care in ovarian cancer management: A review of Gynecologic Oncology Group (GOG)/NRG oncology clinical trials of the past twenty years.

P. DiSilvestro, 2019, Gynecologic oncology.

Phase II study of carboplatin, paclitaxel, and bevacizumab with maintenance bevacizumab as first-line chemotherapy for advanced mullerian tumors.

S. Cannistra, U. Matulonis, N. Horowitz, 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

10 — Focused PlenaryGermline mutations in DNA repair genes in women with ovarian, peritoneal, or fallopian tube cancer treated on GOG protocols 218 and 262

T. Walsh, M. King, E. Swisher, 2014 .

Inhibition of DUSP6 sensitizes ovarian cancer cells to chemotherapeutic agents via regulation of ERK signaling response genes

J. Emerson, N. Yano, C. Chichester, 2019, Oncotarget.

Multiple biomarker algorithms to predict epithelial ovarian cancer in women with a pelvic mass: Can additional makers improve performance?

Richard G. Moore, K. Robison, R. Strongin, 2019, Gynecologic oncology.

Treatment of Cervical Intraepithelial Neoplasia Levels 2 and 3 with Adapalene, a Retinoid‐Related Molecule

M. Pfahl, R. Mannel, P. DiSilvestro, 2001, Journal of lower genital tract disease.

Maintenance olaparib following platinum-based chemotherapy in newly diagnosed patients (pts) with advanced ovarian cancer (OC) and a BRCA1/2 mutation (BRCAm): Phase III SOLO1 trial.

A. Oza, M. Friedlander, C. Aghajanian, 2018, Annals of oncology : official journal of the European Society for Medical Oncology.

A phase I/II study of ruxolitinib with frontline neoadjuvant and post-surgical therapy in patients with advanced epithelial ovarian, Fallopian tube, or primary peritoneal cancer.

R. Burger, D. Mutch, C. Landen, 2022, Journal of Clinical Oncology.